CURE icon

Direxion Daily Healthcare Bull 3X ETF

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 100%
Negative

Neutral
Seeking Alpha
14 days ago
CURE: Pullback In Healthcare Stocks Presents A Buying Opportunity
The Direxion Daily Healthcare Bull 3X ETF (CURE) has slipped in early 2026 as investors take profits after a strong performance in late 2025. The correction in healthcare stocks comes even as analysts envisage significant gains for CURE's ten largest holdings over the next 12 months. This dynamic may present an opportunity to rotate into CURE from the unlevereged XLV ETF, which tracks the same underlying index.
CURE: Pullback In Healthcare Stocks Presents A Buying Opportunity
Neutral
ETF Trends
2 months ago
Which Sector Topped the Leaderboard for January Returns?
The first month of 2026 is already in the books. Which sector walked away with the top spot when it came to total returns?
Which Sector Topped the Leaderboard for January Returns?
Positive
Seeking Alpha
4 months ago
CURE: The Leveraged ETF That Turbocharges The Leading U.S. Healthcare Stocks
Direxion Daily Healthcare Bull 3X Shares ETF has surged 83.5% since August 2025, reflecting bullish momentum in healthcare and pharma sectors. Reduced regulatory uncertainty, successful clinical trials, M&A activity, and prospects for 2026 rate cuts underpin the bullish thesis for CURE. CURE's leveraged structure amplifies both gains and losses, with significant time decay and risk, making it suitable only for tactical trading.
CURE: The Leveraged ETF That Turbocharges The Leading U.S. Healthcare Stocks
Neutral
Seeking Alpha
4 months ago
CURE: Analysts Strike A Cautious Tone Heading Into 2026
The Direxion Daily Healthcare Bull 3X Shares ETF has meaningfully outperformed the S&P 500 so far in 2025, benefiting from a recent shift in sentiment toward health care stocks. While CURE's underlying index is not as cheap as it was a few months ago, it still offers a roughly 19% forward P/E discount relative to the S&P 500. After strong recent returns, analysts project modest single-digit gains over the next 12 months for CURE's largest holdings.
CURE: Analysts Strike A Cautious Tone Heading Into 2026
Positive
ETF Trends
5 months ago
Direxion's 5 Single-Stock ETFs, Including Coinbase and Robinhood
Direxion continues to expand its single-stock ETF offerings for tactical traders. It has introduced five new single stock funds that add exposure to Oracle, Coinbase, Robinhood, and Intel.
Direxion's 5 Single-Stock ETFs, Including Coinbase and Robinhood
Neutral
ETF Trends
5 months ago
Top Performing Leveraged/Inverse ETFs: 11/16/2025
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Top Performing Leveraged/Inverse ETFs: 11/16/2025
Neutral
ETF Trends
5 months ago
These Stocks Could Be Catalysts for CURE
The healthcare sector is catching some flack, and rightfully so. For the three years ending October 15, the S&P Health Care Select Sector Index returned just 22.9%.
These Stocks Could Be Catalysts for CURE
Positive
Benzinga
7 months ago
Direxion's Ultra-Leveraged CURE ETF Offers An Opportunity To Play The Potential Valuation Reset
Amid rising concerns about stagflation, investors have continued to bid up the equities sector. As evidence, the benchmark S&P 500 sector is up over 13% year-to-date.
Direxion's Ultra-Leveraged CURE ETF Offers An Opportunity To Play The Potential Valuation Reset
Neutral
ETF Trends
7 months ago
Healthcare Sector Could Be on the Comeback Trail
Large-cap momentum names have been pushing the healthcare sector aside. Investors have primarily been flocking to Magnificent Seven names benefiting from the artificial intelligence (AI) push.
Healthcare Sector Could Be on the Comeback Trail
Negative
Seeking Alpha
7 months ago
CURE: Adding Defensive Exposure Amid Frothy Market Valuations
The Direxion Daily Healthcare Bull 3X Shares ETF tracks an index composed of U.S. healthcare stocks. While the healthcare sector as a whole is essentially flat in 2025, the effect of beta slippage and a high expense ratio has resulted in CURE underperforming unleveraged ETFs. Looking ahead, CURE's underlying index trades at just 17.3x its forward earnings estimates, a wide discount relative to the S&P 500.
CURE: Adding Defensive Exposure Amid Frothy Market Valuations